Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SALCS 2022 | Anti-GPC3 CAR-T cell therapies in hepatocellular carcinoma

Mitchell Ho, PhD, National Institutes of Health, Bethesda, MD, discusses GPC3 as a target for CAR-T cell therapies in liver cancer. GPC3 is involved in wnt and YAP signaling and anti-human GPC3 antibody (YP7) have been incorporated in several CAR-T cell therapies. In vivo and in vitro studies have demonstrated promising efficacy of this emerging treatment and the CAR-T cell therapy is currently being assessed in a clinical trial in patients with hepatocellular carcinoma. This interview took place at the 2022 San Antonio Liver Cancer Symposium (SALCS) in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.